Ruixin Medical Secures Nearly RMB 300 Million Series B Funding Led by Tencent, Pioneering Clinical Adoption of Intelligent Cardiovascular Diagnostics

VCBeat (WeChat ID: vcbeat) has learned that RayHeart Medical recently officially announced the completion of its Series B financing, raising nearly RMB 300 million. The round was led by Tencent, with existing shareholder Matrix Partners China participating as a co-investor. China Renaissance served as the exclusive financial advisor for this financing round.

This financing round marks a milestone. Following this investment, the company will dedicate itself to the large-scale commercial promotion of Ruixin Medical’s integrated “functional + morphological” platform products. By collaborating with partners to facilitate hospital adoption, the company aims to help healthcare professionals optimize diagnostic and treatment workflows, thereby enabling non-invasive, precise diagnosis of cardiovascular and cerebrovascular diseases. Simultaneously, it will strengthen the closed-loop layout of its intelligent cardiovascular and cerebrovascular platform, encompassing large-scale screening, precise diagnosis, preoperative and intraoperative guidance, as well as postoperative chronic disease management. This will accelerate the widespread clinical application and commercial implementation of intelligent healthcare solutions.

Ruixin Medical is committed to building a top-tier professional team. Starting from clinical needs, the company promotes the research and development and clinical application of technologies such as AI and cloud computing with a professional attitude. Its first product is an innovative non-invasive coronary blood supply function assessment system—Ruixin-FFR. The company completed the largest-scale prospective multi-center clinical trial in the shortest time frame within the industry, achieving globally leading product performance. Meanwhile, by establishing an elite business team, it has explored hospital adoption models and facilitated routine trials in nearly 200 hospitals. Under the company’s leadership, a blue-ocean market worth tens of billions of yuan is rapidly emerging.

The founding team of Ruixin Medical has accumulated over ten years of technical expertise and experience in directly related fields in the United States, demonstrating precise insight into and control over clinical needs, product forms, and technological development. The Ruixin-FFR product fills a gap in the diagnosis of cardiovascular and cerebrovascular diseases, addresses two key pain points in the diagnostic and treatment workflow, and boasts broad market potential and application prospects. First, there is an urgent clinical need for a product that can deliver non-invasive, simple, and accurate diagnoses, a critical demand met by Ruixin-FFR. Furthermore, while current clinical products provide only morphological information, Ruixin Medical offers an integrated platform combining “morphology + function.” By adding a functional dimension to purely image-based morphological diagnosis, this approach yields more comprehensive and precise results.

Meanwhile, Ruixin Medical has developed a series of platform-based product pipelines focused on the cardiovascular and cerebrovascular fields, covering cardiovascular, cerebrovascular, and peripheral vascular areas. The company has established a closed-loop layout spanning screening, precision diagnostics, preoperative and intraoperative guidance, and postoperative chronic disease management.

According to the "Report on Cardiovascular Health and Diseases in China 2019" released by the National Center for Cardiovascular Diseases, the prevalence of cardiovascular diseases in China is on a continuous rise, with an estimated 330 million current patients, and mortality from these conditions remains the leading cause of death. There is considerable uncertainty in the diagnostic and therapeutic processes for cerebrovascular and cardiovascular diseases. Taking the diagnosis and treatment of coronary heart disease as an example, clinicians’ decisions on whether to implant stents are based on the degree of stenosis shown in imaging; however, this result does not accurately assess whether the diseased vessel can provide adequate blood flow. Large-scale clinical studies have shown that among cases with moderate stenosis (defined as 50%–70% narrowing, for which clinical guidelines generally do not recommend stenting), the proportion of myocardial ischemia reaches 35%; whereas among cases with severe stenosis (defined as 70%–90% narrowing, for which clinical guidelines typically recommend stent therapy), the proportion of normal myocardial perfusion reaches 20%.

Fractional Flow Reserve (FFR), as a novel diagnostic modality, evaluates whether the severity of coronary artery stenosis causes myocardial ischemia from the perspective of perfusion function. Invasive FFR measurement using a pressure wire is recognized by expert consensus as the most accurate gold standard for diagnosing stable coronary artery disease, holding the highest recommendation level (Class I, Level A) in clinical guidelines. Meanwhile, Rainy Heart Fraction, based on non-invasive CTA imaging, utilizes advanced intelligent and scientific algorithms to calculate FFR—a key indicator of perfusion function across the entire coronary system—without requiring additional interventional procedures. By integrating anatomical and functional assessments in a completely non-invasive manner, it offers the advantages of being “efficient, non-invasive, precise, and one-stop.” Currently, similar products abroad have achieved large-scale commercial adoption through insurance coverage in regions such as the United States, Europe, and Japan. Domestically, this field is emerging, with fee-for-service pricing schedules gradually being implemented across various provinces and cities in China. The clinical demand is clear, the commercial scenario is well-defined, and the market potential is substantial.

Ruixin Medical’s three founders—Zheng Lingxiao, Lan Hongzhi, and Ma Jun—each possess over ten years of R&D experience in the United States (including at Johns Hopkins University, Stanford University, and with the da Vinci Surgical System) in the core technological domain of Ruixin-FFR. Building on this foundation, Ruixin Medical has continuously recruited high-caliber experts across various fields to further broaden and deepen the company’s competitive moat in the field of intelligent medical imaging. In March 2020, the Ruixin-FFR product received approval from the National Medical Products Administration (NMPA) as an innovative medical device, becoming one of the first intelligent medical imaging products to enter the NMPA’s innovative approval pathway for Class III AI medical devices. By May 2020, it had completed a large-scale prospective clinical validation involving 330 cases—nearly 100 more than the largest trial conducted globally up to that point. The results demonstrated that its sensitivity, specificity, accuracy, and other key metrics all reached internationally leading levels.

RuiXin Medical’s business team brings over a decade of sales and marketing experience in the cardiovascular and cerebrovascular fields, and is vigorously advancing the clinical application of RuiXin’s products to accelerate the nationwide deployment and promotion of its portfolio, including the RuiXin Fraction (FFR) series. Currently, RuiXin has established clinical and research collaborations with leading medical institutions in the cardiovascular and cerebrovascular specialties, such as Fuwai Hospital, Anzhen Hospital, and Zhongshan Hospital Fudan University. The RuiXin Fraction has been implemented in nearly 200 hospitals, positioning the company at the forefront of commercial adoption across the sector.

It is reported that, in addition to the Ruixin Score, the company has completed the research and development as well as clinical validation of multiple products, initially achieving a platform-based layout. These products include: an intelligent analysis and reporting system for cardiovascular and cerebrovascular imaging; a stroke warning system; a surgical planning system for aortic dissection and aortic aneurysm; a product for assessing blood supply function based on interventional coronary angiography; intelligent analysis based on intravascular ultrasound (IVUS); vascular plaque risk assessment; and surgical planning for coronary stenting and bypass grafting. Together, these offerings provide clinicians with a comprehensive, one-stop intelligent solution.

Zheng Lingxiao, Founder of Reii Medical, stated, “Reii Medical has always firmly believed that innovation in hard technology is the core driver of China’s next decade, and that cutting-edge technologies should better address clinical pain points and achieve successful commercial implementation. ReiiFFR marks Reii Medical’s entry into the market. The company is committed to building an intelligent, integrated platform for cardiovascular and cerebrovascular care, covering the fields of cardiovascular, cerebrovascular, and peripheral vascular diseases. This platform aims to provide comprehensive coverage across multiple departments—including radiology, cardiology, cardiac surgery, neurosurgery, interventional medicine, and vascular surgery—and to establish a closed-loop chain encompassing large-scale screening, precise diagnosis, intraoperative and preoperative guidance, as well as chronic disease management.”

Yao Leiwen, Managing Director of Tencent Investment, stated: “Tencent continues to closely monitor the integration of AI technology with healthcare and the application opportunities for intelligent medical products in clinical settings. The Reixin team is an outstanding group deeply entrenched in this field, boasting substantial technological and R&D expertise. Its core product, CT-FFR, provides clinicians with critical diagnostic information, helping to optimize diagnosis and treatment pathways, thereby demonstrating significant clinical and commercial value. We look forward to the company’s continued development and innovation, contributing to technological advancements in the healthcare industry, ensuring that technological progress benefits the public and serves humanity.”

As an investor in RayHeart Medical’s Series A financing round, Sun Linghao, Vice President of Matrix Partners China, stated, “Against the backdrop of volume-based procurement for coronary stents, precise non-invasive diagnosis of vascular diseases has become a clinical necessity and a key demand from physicians, gradually reshaping standard clinical pathways. The RayHeart team conducted the first large-scale prospective clinical trial in the CT-FFR field in China, demonstrating its keen insight into clinical needs and its capability to drive high-quality clinical trials. We look forward to RayHeart’s continued advancement in the commercialization of multiple products, providing patients with precise and accessible novel diagnostic technologies, and establishing itself as a leading company in intelligent cardiovascular and cerebrovascular diagnosis.”

Zhou Xiang, Head of the Financial Advisory Division at China Renaissance, stated, “The large-scale clinical application and commercialization of FFR, a functional diagnostic test, in the cardiovascular and cerebrovascular fields have become a clear trend, with all indicators pointing strongly in this direction. With its CT-FFR product as a breakthrough, Ruixin has taken root in the cardiovascular and cerebrovascular sector, committed to ensuring that every blood vessel receives the earliest possible diagnosis and the most precise treatment. China Renaissance is honored to have assisted Ruixin in completing this financing round, and we believe that the company will continue to leverage its existing advantages to create greater value for patients and physicians alike.”